Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Nov 14, 2022 4:09pm

109 Views

Post# 35097784

Recent News

AGN.c AGNPF has had a steady stream of news over the past several weeks.

Last month they entered an Investigator-Initiated Clinical Trial Agreement with Yale University for the investigation of DMT for the treatment of depression.

Then AGN announced last week they were granted permission to conduct a phase 1 study of DMT for the treatment of strokes. The phase 1 study is expected to begin before the end of the year.

The global stroke treatment market was valued at $8B in 2018 and is expected to reach $15B by 2027. With the positive sentiments around DMT as treatment growing I think AGN is in a solid spot to capitalize.

https://ir.algernonpharmaceuticals.com/news-events/press-releases

<< Previous

Bullboard Posts

Next >>

Two Venture-listed mining stocks file NI 43-101 reports